

ROBIN OligoMET Center

Monthly Research Update: November 2023

Publications

NOVEMBER AT A GLANCE TOTALS	
Publications	9
Grants and contracts	
New awards	0
Submitted	1
Oral Presentations	1
Abstracts	0
Clinical trials	
TERPS	2
Awards/Honors	0

Please submit all monthly updates to Jadyne Stewart at jadynstewart@som.umaryland.edu by second Wednesday of each month.

- Beg S, Zanettini C, Queiroz L, **Marchionni L**, Alperstein SA, Siddiqui MT. [Optimal fluid volume for detecting malignancy in serous effusions: a single institution experience](#). *J Am Soc Cytopathol*. 2023 Nov-Dec;12(6):415-422. doi: 10.1016/j.jasc.2023.06.003. Epub 2023 Jun 13. PMID: 37419704.
- Benedetti E, Chetnik K, Flynn T, Barbieri CE, Scherr DS, **Loda M**, Krumsiek J. [Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort](#). *Sci Data*. 2023 Nov 25;10(1):830. doi: 10.1038/s41597-023-02750-7. PMID: 38007532; PMCID: PMC10676366.
- Constine LS, Marks LB, Milano MT, Ronckers CM, Jackson A, Hudson MM, Marcus KJ, Hodgson DC, Hua CH, Howell RM, Marples B, Yorke E, Olch A, **Bentzen SM**. [A User's Guide and Summary of Pediatric Normal Tissue Effects in the Clinic \(PENTEC\): Radiation Dose-Volume Response for Adverse Effects After Childhood Cancer Therapy and Future Directions](#). *Int J Radiat Oncol Biol Phys*. 2023 Nov 23:S0360-3016(23)07918-X. doi: 10.1016/j.ijrobp.2023.09.005. Epub ahead of print. PMID: 37999712.
- Elnaggar M, Chaisuparat R, Ghita I, **Bentzen SM**, Dyalram D, Ord RA, Lubek JE, Younis RH. [Immuno-oncologic signature of malignant transformation in oral squamous cell carcinoma](#). *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2023 Nov;136(5):612-622. doi: 10.1016/j.oooo.2023.07.009. Epub 2023 Jul 13. PMID: 37739913.
- Geng C, Zhang MC, Manyam GC, Vykoukal JV, Fahrman JF, Peng S, Wu C, Park S, Kondraganti S, Wang D, Robinson BD, **Loda M**, Barbieri CE, Yap TA, Corn PG, Hanash S, Broom BM, Pilié PG, Thompson TC. [SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression](#). *Clin Cancer Res*. 2023 Nov 1;29(21):4464-4478. doi: 10.1158/1078-0432.CCR-23-1439. PMID: 37581614; PMCID: PMC11017857.
- Gheybi K, Mmekwa N, Lebelo MT, Patrick SM, Campbell R, Nenzhelele M, Soh PXY, Obida M, **Loda M**, Shirindi J, Butler EN, Mutambirwa SBA, Bornman MSR, Hayes VM. [Linking African ancestral substructure to prostate cancer health disparities](#). *Sci Rep*. 2023 Nov 27;13(1):20909. doi: 10.1038/s41598-023-47993-x. PMID: 38017150; PMCID: PMC10684577.
- Jiang Z, Wang S, Xu Y, Sun L, Gonzalez G, Chen Y, Wu QJ, Xiang L, **Ren L**. [Radiation-induced acoustic signal denoising using a supervised deep learning framework for imaging and therapy monitoring](#). *Phys Med Biol*. 2023 Nov 29;68(23):10.1088/1361-6560/ad0283. doi: 10.1088/1361-6560/ad0283. PMID: 37820684; PMCID: PMC11000456.
- Omar M**, Nuzzo PV, Ravera F, Blevé S, Fanelli GN, Zanettini C, Valencia I, **Marchionni L**. [Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer](#). *J Transl Med*. 2023 Nov 15;21(1):811. doi: 10.1186/s12967-023-04713-3. PMID: 37964363; PMCID: PMC10647131.
- Xu Z, Li Q, **Marchionni L**, Wang K. [PhenoSV: interpretable phenotype-aware model for the prioritization of genes affected by structural variants](#). *Nat Commun*. 2023 Nov 28;14(1):7805. doi: 10.1038/s41467-023-43651-y. PMID: 38016949; PMCID: PMC10684511.

ROBIN OligoMET Center
Monthly Research Update: November 2023

Grants and Contracts

Funded:

- None reported.

Submitted:

- **Phuoc Tran, MD PhD, PI/PD**, as a subaward with University of Miami, to NIH/NCI PA-20-185 for “Transcriptomic Signatures to direct postoperative treatment of prostate cancer after biomedical failure” (R01; resubmission; \$1,347,413).

Oral Presentations

- **Phuoc T.**, SUO Annual Meeting, Session – Castration-Sensitive Prostate Cancer (November 28, 2023 – Washington DC). “Contemporary Radiotherapy Management of Oligometastatic Castration-Sensitive Prostate Cancer”.

Abstracts

- None reported

Clinical Trial Enrollment

- 2 patient was enrolled (16/122 total) on the **TERPS trial**.

Awards/Honors

- None reported

Please note that these examples are representative of productivity from the ROBIN OligoMET Center members and are not exclusively attributable to the U54 grant.